Vallianatou T

Applying Spatial Metabolomics To Investigate Age- and Drug-Induced Neurochemical Changes.

Vallianatou T, Angerer TB, Kaya I, ..., Svenningsson P, Andrén PE

ACS Chem Neurosci 15 (15) 2822-2829 [2024-08-07; online 2024-07-29]

Spatial Mass Spectrometry [Collaborative]

Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson's disease primate model.

Kaya I, Nilsson A, Luptáková D, ..., Bezard E, Andrén PE

NPJ Parkinsons Dis 9 (1) 118 [2023-07-26; online 2023-07-26]

Spatial Mass Spectrometry [Technology development]

Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems.

Fridjonsdottir E, Vallianatou T, Mantas I, ..., Svenningsson P, Andrén PE

ACS Chem. Biol. 17 (1) 147-158 [2022-01-21; online 2021-12-21]

Spatial Mass Spectrometry [Technology development]

Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier.

Luptáková D, Vallianatou T, Nilsson A, ..., Loryan I, Andrén PE

Mol. Psychiatry - (-) - [2021-09-03; online 2021-09-03]

Spatial Mass Spectrometry [Technology development]

Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain.

Vallianatou T, Shariatgorji R, Nilsson A, ..., Svenningsson P, Andrén PE

ACS Chem Neurosci 12 (10) 1811-1823 [2021-05-19; online 2021-05-03]

Spatial Mass Spectrometry [Technology development]

Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.

Fridjonsdottir E, Shariatgorji R, Nilsson A, ..., Bezard E, Andrén PE

Sci Adv 7 (2) - [2021-01-00; online 2021-01-06]

Spatial Mass Spectrometry [Technology development]